[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Xiaotong Hou\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":91},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,63],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100537263","use-of-bivalirudin-for-anticoagulation-in-patients-with-extracorporeal-membrane-oxygenation-100537263",false,"NCT06275555","Use of Bivalirudin for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation","Efficacy and Safety of Bivalirudin Versus Heparin in Anticoagulant Therapy of ECMO: a Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age ≥ 18 years old\n2. Accept VA-ECMO or VV-ECMO\n3. the ECMO team believes that systemic anticoagulation is necessary and that APTT should be maintained at 40-60s.\n4. sign the informed consent form\n\nExclusion Criteria:\n\n1. previous history of allergy to heparin or bivalirudin\n2. previous diagnosis of heparin-induced thrombocytopenia.\n3. the pre-random ECMO assistance time is more than 48 hours.\n4. pregnant female\n5. have participated in this study before.\n6. the researchers believe that there are other factors that are not suitable to participate in this study.","ALL","18 Years",{"count":19,"type":20},154,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this study was to evaluate the efficacy and safety of bivalirudin in anticoagulation therapy in patients with extracorporeal membrane oxygenation (ECMO) compared with unfractionated heparin.",[26],"Extracorporeal Membrane Oxygenation Complication","RECRUITING","2026-04-02",{"date":30,"type":31},"2026-04-06","ACTUAL",{"date":33,"type":31},"2024-06-03",{"date":35,"type":20},"2027-03-01",{"name":37,"class":38},"Xiaotong Hou","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":49,"briefSummary":50,"conditions":51,"keywords":52,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":39},"100537298","use-of-nafamostat-mesilate-for-anticoagulation-in-patients-with-ecmo-100537298","NCT06276010","Use of Nafamostat Mesilate for Anticoagulation in Patients With ECMO","Use of Nafamostat Mesilate for Anticoagulation in Patients With Extracorporeal Membrane Oxygenation After Cardiac Surgery: Efficacy and Safety","Inclusion Criteria:\n\n1. Age ≥ 18 years old\n2. VA-ECMO or VV-ECMO was accepted after cardiac surgery.\n3. The ECMO treatment team believes that systemic anticoagulation is needed\n4. Sign the informed consent form\n\nExclusion Criteria:\n\n1. The researchers believe that there are other causes of active bleeding that are not suitable to participate in this study.\n2. Long-term use of anticoagulants before establishment of ECMO\n3. Antiplatelet drugs were used before the establishment of ECMO\n4. Severe liver insufficiency\n5. Connective tissue disease\n6. There is a history of allergy to heparin or nemolastat mesylate.\n7. Pregnant\n8. Previous diagnosis of heparin-induced thrombocytopenia\n9. Expect to die within 48 hours\n10. ECPR",{"count":48,"type":20},80,[23],"The purpose of this study is to evaluate the effectiveness and safety of nafamostat mesilate compared with unfractionated heparin for anticoagulation in patients with ECMO after cardiac surgery.",[26],[53,54],"anticoagulation","nafamostat mesilate","2025-09-22",{"date":57,"type":31},"2025-09-25",{"date":59,"type":31},"2024-07-01",{"date":61,"type":20},"2026-12-31",{"name":37,"class":38},{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":71,"targetDuration":73,"studyType":74,"phases":4,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":39},"100582391","effect-of-reduced-vasopressors-on-mortality-in-ecmo-supported-cardiogenic-shock-patients-100582391","NCT06862700","Effect of Reduced Vasopressors on Mortality in ECMO-supported Cardiogenic Shock Patients","Association Between Vasopressor Exposure Levels and 30-Day Mortality in Patients Receiving ECMO Support for Cardiogenic Shock: A Prospective Multicenter Cohort Study","VREM-CS","Inclusion Criteria:\n\n* Adults (≥18 years) with cardiogenic shock requiring VA-ECMO support.\n* First-time ECMO initiation.\n* Venoarterial ECMO (VA-ECMO) as the initial mode.\n\nExclusion Criteria:\n\n* Age \\\u003C18 years.\n* Severe pulmonary hypertension.\n* Vasopressor use for non-shock indications (e.g., bleeding, post-cardiopulmonary bypass vasoplegia).\n* Severe missing data.",{"count":72,"type":20},534,"30 Days","OBSERVATIONAL","The goal of this observational study is to learn about the association between vasopressor exposure levels and outcomes in adults with cardiogenic shock receiving VA-ECMO. The main question it aims to answer is:\n\nDoes reduced exposure to vasopressors lower the 30-day mortality in patients with cardiogenic shock when receiving ECMO support? Participants who are receiving ECMO support for cardiogenic shock as part of their regular medical care will have their data collected, including information about their vasopressor use and mortality outcomes, over the course of the study.",[77,78,79,80,81,82],"Cardiogenic Shock","Extracorporeal Membrane Oxygenation","Vasopressors","Hemodynamic Management","Critical Care","Heart Failure","2025-03-04",{"date":85,"type":31},"2025-03-06",{"date":87,"type":31},"2025-02-26",{"date":89,"type":20},"2028-01-01",{"name":37,"class":38},""]